0001561032-24-000009.txt : 20240329 0001561032-24-000009.hdr.sgml : 20240329 20240329071032 ACCESSION NUMBER: 0001561032-24-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240327 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Trust, Inc. CENTRAL INDEX KEY: 0001561032 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 383888962 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39153 FILM NUMBER: 24801989 BUSINESS ADDRESS: STREET 1: 222 BELLEVUE AVENUE CITY: NEWPORT STATE: RI ZIP: 02840 BUSINESS PHONE: 212-415-6500 MAIL ADDRESS: STREET 1: 222 BELLEVUE AVENUE CITY: NEWPORT STATE: RI ZIP: 02840 FORMER COMPANY: FORMER CONFORMED NAME: American Realty Capital Healthcare Trust II, Inc. DATE OF NAME CHANGE: 20121025 8-K 1 hct-20240327.htm 8-K hct-20240327
FALSE000156103200015610322024-03-272024-03-270001561032hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember2024-03-272024-03-270001561032hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember2024-03-272024-03-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  March 27, 2024
 
Healthcare Trust, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Maryland 001-39153 38-3888962
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I.R.S. Employer
Identification No.)
 
222 Bellevue Ave.
Newport, RI 02840
__________________________________________________________________________________________________________________________________________________________________________
(Address, including zip code, of Principal Executive Offices)

Registrant’s telephone number, including area code: (212) 415-6500
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per shareHTIAThe Nasdaq Global Market
7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per shareHTIBPThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




Item 8.01. Other Events
Determination of Estimated Per-Share Net Asset Value
Overview
The board of directors (the “Board”) of Healthcare Trust, Inc. (the “Company”) has previously adopted valuation guidelines used in connection with determining the estimated per-share net asset value (“Estimated Per-Share NAV”) of the Company’s common stock. Under these guidelines, the Company publishes an Estimated Per-Share NAV on at least an annual basis. Healthcare Trust Advisors, LLC, the Company's advisor (the “Advisor”), calculates the Estimated Per-Share NAV taking into consideration appraisals of the Company’s real estate assets (each asset individually, a “Real Estate Asset” and collectively, the “Real Estate Assets”) which are performed by an independent valuation firm in accordance with the valuation guidelines. The Advisor reviews these valuations both for consistency with the valuation guidelines and for the reasonableness of the independent valuation firm’s conclusions. The independent directors of the Board ultimately make the final determination of Estimated Per-Share NAV. The independent directors of the Board rely on the Advisor’s input, including its view of the estimate and the appraisals performed by the independent valuation firm, but may, in the Board's discretion, consider other factors.
On March 27, 2024, the independent directors of the Board, who comprise a majority of the Board unanimously approved an Estimated Per-Share NAV as of December 31, 2023 (the “Valuation Date”) equal to $13.00. The Estimated Per-Share NAV of $13.00 selected by the independent directors of the Board fell within the range of the values reported by Kroll, LLC (formerly known as Duff & Phelps, LLC) (“Kroll), an independent third-party real estate advisory firm engaged by the Company to value its real estate assets and review the valuations of its other assets and liabilities. The range of values provided by Kroll was based on the estimated fair value of the Company’s assets less the estimated fair value of the Company’s liabilities and the liquidation value of the Company's 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the Series A Preferred Stock”), which includes the Company's 100,000 partnership units in the Company's operating partnership designated as “Series A Preferred Units” and the liquidation value of the Company's 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock (the Series B Preferred Stock”), divided by 112,034,251 shares of common stock outstanding as of December 31, 2023. The common stock outstanding amount used to calculate the Estimated Per-Share NAV as of December 31, 2023 includes the dividends declared and issued entirely in shares of the Company's common stock through December 31, 2023, but does not include any other dividend declared and payable in whole or in part in shares of the Company's common stock subsequent to December 31, 2023. Issuing dividends in additional shares of common stock will, all things equal, cause the Estimated Per-Share NAV to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a stock dividend; however, because each stockholder will receive the same proportionate number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers.
In determining the Estimated Per-Share NAV of $13.00, the independent directors of the Board considered various factors, including the information provided by Kroll, the impact of the stock dividend that was issued in January 2024 and the fact that three properties expected to be sold subsequent to December 31, 2023 were valued based on their estimated sale prices and without giving consideration to the reinvestment of the sale proceeds. There have been no other changes between December 31, 2023 and the date of this filing that the Advisor believes would materially impact the overall Estimated Per-Share NAV.
The Estimated Per-Share NAV will not be adjusted for any stock dividend(s) paid in the future until the Board determines a new Estimated Per-Share NAV.
Sensitivity Analysis
The Advisor noted that applying the low, midpoint and high ends of the range of capitalization rates and discount rates used by Kroll resulted in an Estimated Per-Share NAV range equal to $12.01 - $13.60 per share. The midpoint in that range was $12.58 per share.



The capitalization rates and discount rates used have a significant impact on the estimated value of the Real Estate Assets. The following chart presents the impact on the Company’s Estimated Per-Share NAV resulting from variations in the capitalization rates for those properties valued using the Direct Capitalization Method (as defined below) and variations in discount rates for those properties valued using the Discounted Cash Flow Method (as defined below), within the range of values determined by Kroll.
 Range of Value
 LowMidpointHigh
Share Price$12.01 $12.58 $13.60 
Weighted Average Capitalization Rate6.45 %6.71 %6.96 %
Weighted Average Discount Rate (1)
7.81 %8.31 %8.81 %
(1)This analysis shows the effect of varying the discount rate used in the Discounted Cash Flow Method. For purposes of this sensitivity analysis, the weighted average terminal capitalization rate, which applies only to Real Estate Assets valued using the Discounted Cash Flow Method was 7.02%.
Process
Consistent with the Company’s valuation guidelines, Kroll performed appraisals of the Real Estate Assets as of the Valuation Date and provided a valuation range for each Real Estate Asset. In addition, Kroll was engaged to review the Company’s market value estimates regarding other assets, liabilities and the liquidation values of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock as of the Valuation Date. Kroll has extensive experience estimating the fair value of commercial real estate.
The method used by Kroll to appraise the Real Estate Assets in the report furnished to the Advisor and the Board by Kroll (the “Kroll Report”) complies with the Institute of Portfolio Alternatives (formerly known as the Investment Program Association) Practice Guideline 2013-01 titled “Valuations of Publicly Registered Non-Listed REITs,” issued April 29, 2013. Also, Kroll advised that the scope of work performed was conducted in conformity with the requirements of the Code of Professional Ethics and Standards of Professional Practice of the Appraisal Institute. The Company has engaged Kroll for the past nine years to assist the Board in determining the Company's Estimated Per-Share NAV. For preparing the Kroll Report, the Company paid Kroll a customary fee for services of this nature, no part of which was contingent relating to the provision of services or specific findings. Other than its engagement as described herein and its engagements to provide certain purchase price allocation and other real estate valuation services, Kroll does not have any direct interests in any transaction with the Company.
Potential conflicts of interest between Kroll, on one hand, and the Company or the Advisor, on the other hand, may arise as a result of (i) the impact of the findings of Kroll in relation to the Company’s Real Estate Assets, or the assets of real estate investment programs sponsored by affiliates of the Advisor, on the value of ownership interests owned by, or incentive compensation payable to, directors, officers or affiliates of the Company and the Advisor, or (ii) Kroll performing valuation services for other programs sponsored by affiliates of the Advisor, as well as other services for the Company. While the Company and other programs sponsored by affiliates of the Advisor have engaged and may engage Kroll or its affiliates in the future for valuations and real estate-related services of various kinds, the Company believes that there are no material conflicts of interest with respect to the Company's engagement of Kroll.
Valuation Methodology
In preparing its valuation materials and in reaching its conclusion, Kroll, among other things:
performed its valuations on a desktop basis;
relied on information provided by the Company relating to each property’s physical, financial and economic characteristics;
performed a study of each market to measure current market conditions, supply and demand factors, growth patterns and their effect on each of the Real Estate Assets;
reviewed financial and operating information requested from, or provided by, the Company, including property level cash flow and other leasing assumptions for applicable Real Estate Assets;
reviewed other assets and liabilities of the Company, including the Company’s mortgage debt, credit facilities and the liquidation values of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock; and
performed such other analyses and studies, and considered factors, as Kroll considered appropriate.
Kroll valued the Real Estate Assets utilizing an income capitalization approach consisting of either the Direct Capitalization Method or the Discounted Cash Flow Method and certain other approaches, all as described further below. These approaches are commonly used in the commercial real estate industry.



The Estimated Per-Share NAV is generally comprised of (i) the sum of (A) the estimated value of the Real Estate Assets and (B) the estimated value of the other assets, minus (ii) the sum of (C) the estimated value of debt and other liabilities (D) the estimate of the aggregate incentive fees, participations and limited partnership interests held by or allocable to the Advisor, management of the Company or any of their respective affiliates based on the aggregate net asset value of the Company and payable in a hypothetical liquidation of the Company as of the Valuation Date (which was zero as of December 31, 2023), and (E) the liquidation value of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock, divided by (iii) the number of shares of common stock outstanding as of the Valuation Date, which was 112,034,251. In determining the Estimated Per-Share NAV, the independent directors of the Board also considered the impact of other factors described herein that were not specifically quantified. Shares of common stock outstanding for these purposes is the sum of shares of common stock outstanding, including vested and unvested restricted shares, and partnership units of the Company's operating partnership designated as “OP Units” (“OP Units”), excluding performance-based restricted partnership units of the Company’s operating partnership designated as “Class B Units” (“Class B Units”) because the Advisor concluded that, in a hypothetical liquidation at such Estimated Per-Share NAV, it may not be entitled to any incentive fees or Class B Units. The Advisor determined the Estimated Per-Share NAV in a manner consistent with the definition of fair value under U.S. generally accepted accounting principles set forth in FASB’s Topic ASC 820, Fair Value Measurements and Disclosures.
Income Capitalization Approach
Kroll estimated a range of “as is” market value for substantially all of the Real Estate Assets as of December 31, 2023 using primarily the income capitalization approach, which simulates the reasoning of an investor who views the cash flows that would result from the anticipated revenue and expense on a property throughout its projection period. The net income developed in Kroll’s analysis is the balance of potential income remaining after vacancy and collection loss and operating expenses. This net income was then capitalized at an appropriate rate to derive an estimate of value (the “Direct Capitalization Method”) or discounted by an appropriate yield rate over a typical projection period in a discounted cash flow analysis (the “Discounted Cash Flow Method”). The Direct Capitalization Method was used for stabilized real estate assets, and the Discounted Cash Flow Method was used for real estate assets that were not stabilized or which had leases with irregular rent escalations. Thus, two key steps were involved: (i) estimating the net income applicable to each Real Estate Asset, and (ii) choosing appropriate capitalization rates and discount rates, as applicable.
Other Approaches
Kroll utilized a sales comparison approach (the “Sales Comparison Approach”) to estimate the market value of the Company's two vacant land parcels based on what other purchasers and sellers in the applicable market had agreed to as a price for comparable vacant land parcels. This approach is based on the principle of substitution, which states that the limits of prices, rents and rates tend to be set by the prevailing prices, rents and rates of equally desirable substitutes.
Kroll utilized the contract purchase price (the “Acquisition Method”) to estimate the value of seven recently acquired Medical Office Buildings.
Kroll utilized the estimated sales price (the “Disposition Method”) to estimate the value of two Seniors Housing Properties, one of which was sold subsequent to December 31, 2023, and one MOB property.
Summary of Approaches
Kroll utilized the Discounted Cash Flow Method for 177 Real Estate Assets, the Direct Capitalization Method for 15 Real Estate Assets, the Acquisition Method for seven Real Estate Assets, the Disposition Method for three Real Estate Assets and the Sales Comparison Approach for two Real Estate Assets.
Kroll changed the valuation approach for 14 Seniors Housing Properties from Direct Capitalization Method as of December 31, 2022 to the Discounted Cash Flow Method as of December 31, 2023, reflecting the fact that the cash flows from these properties were negatively impacted and are expected to stabilize over time. Also, Kroll changed the valuation approach for two Seniors Housing Properties from the Discounted Cash Flow Method as of December 31, 2022, to the Direct Capitalization Method as of December 31, 2023, which reflects cash flow stabilization at these properties.



The following table presents the valuation methodology by property type:
Income Capitalization ApproachOther Approaches
Discounted Cash Flow MethodDirect Capitalization MethodAcquisition MethodDisposition MethodSales Comparison ApproachTotal
Medical Office Buildings146271156
Seniors Housing Properties31132248
Total17715732204
Estimated Per-Share NAV
The following table, prepared by the Advisor, summarizes the individual components of the low, midpoint and high values of the Real Estate Assets estimated by Kroll and the Advisor’s estimate of the values of the Company's other assets and liabilities. The Estimated Per-Share NAV approved by the Board of $13.00 was $0.42 per share above the midpoint of the range provided in the Kroll Report and considered various factors. See the “Overview” section above for additional discussion of these considerations. The shares of common stock outstanding used in the calculation of the Estimated Per-Share Nav were 112,034,251 and 105,541,612 as of December 31, 2023 and 2022, respectively, which represents an increase of approximately 6% of outstanding shares. The 6% increase in outstanding shares is one component, among many, of the change in per share range of values detailed in the table below.
As stated above, issuing dividends in additional shares of common stock will, all things equal, cause the Estimated Per-Share NAV to decline because the number of shares outstanding increases when shares of common stock are issued in respect of a stock dividend; however, because each stockholder will receive the same proportionate number of new shares, the total value of a common stockholder’s investment, all things equal, will not change assuming no sales or other transfers.
December 31, 2023
December 31, 2022
Range of ValuesFinalFinal
 LowMidpointHigh
Real Estate Assets (1)
$23.22 $23.79 $24.81 $24.21 $25.23 
Other Assets (2)
0.98 0.98 0.98 0.98 0.91 
Derivative Assets, at fair value (3)
0.25 0.25 0.25 0.25 0.39 
Fair Value of Debt (4)
(10.26)(10.26)(10.26)(10.26)(10.26)
Other Liabilities (5)
(0.46)(0.46)(0.46)(0.46)(0.44)
Series A Preferred Stock (6)
(0.91)(0.91)(0.91)(0.91)(0.97)
Series B Preferred Stock (7)
(0.81)(0.81)(0.81)(0.81)(0.86)
Kroll Range of Values$12.01 $12.58 $13.60 $13.00 $14.00 
(1)The low value of the Real Estate Assets approximates, and the midpoint and high values of the Real Estate Assets reflect overall increases of 2.3% and 6.6% above, the net of (i) the aggregate carrying value of the Real Estate Assets, at cost of $2.6 billion, and (ii) the gross market lease intangible liabilities of $23.5 million. Cumulative impairment charges on properties owned as of December 31, 2023 totaled $27.9 million, and are reflected within real estate, at cost. The key assumptions that were used by Kroll in its models to estimate the value of each Real Estate Asset are set forth below:
The following summarizes the range of capitalization rates used to arrive at the estimated market values of the Real Estate Assets valued utilizing the Direct Capitalization Method as of December 31, 2023:
 RangeWeighted
Average
Capitalization Rate6.25% — 8.25%6.71%
The following summarizes the range of terminal capitalization rates and discount rates used to arrive at the estimated market values of the Real Estate Assets valued utilizing the Discounted Cash Flow Method as of December 31, 2023:
 RangeWeighted
Average
Terminal Capitalization Rate5.50% — 9.50%7.02%
Discount Rate6.25% — 12.75%8.31%



(2)Includes the following line items from the Company’s audited financial statements: (i) cash and cash equivalents; (ii) restricted cash; and (iii) prepaid expenses and other assets, adjusted for certain items. The Advisor believes that the carrying values of these assets estimate their fair values.
(3)As disclosed in Note 6 - Fair Value of Financial Instruments to the Company’s audited consolidated financial statements in the Company’s Annual Report on Form 10-K, the valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
(4)As disclosed in Note 6 - Fair Value of Financial Instruments to the Company’s audited consolidated financial statements in the Company’s Annual Report on Form 10-K, the value of the Company’s mortgage notes payable was estimated using a discounted cash flow analysis. The inputs into the discounted cash flow analysis were based on the Advisor’s experience with similar types of borrowing arrangements. Advances under the Company's credit facilities are considered to be reported at fair value, because the interest rates on the credit facilities vary with changes in SOFR.
(5)Includes the following line items from the Company’s audited financial statements: (i) accounts payable and accrued expenses (including amounts due to related parties); (ii) deferred rent; and (iii) distributions payable. The Advisor believes that the carrying values of these liabilities estimate their fair values.
(6)Series A Preferred Stock was initially issued in December 2019. Amount represents the liquidation value of the 3,977,144 shares of Series A Preferred Stock and the 100,000 units of Series A Preferred Units outstanding as of December 31, 2023 with a liquidation preference of $25.00 per share.
(7)Series B Preferred Stock was initially issued in October 2021. Amount represents the liquidation value of the 3,630,000 shares of Series B Preferred Stock outstanding as of December 31, 2023 with a liquidation preference of $25.00 per share.
Limitations of the Asset Appraisals
The Company believes that the assumptions described herein to estimate the value of the Real Estate Assets are within the ranges used by market participants buying and selling similar properties, assuming a willing buyer and a willing seller, neither being under any compulsion to buy or to sell. The estimated values of the Real Estate Assets may not, however, represent current market value or book value. Real properties are currently carried at their amortized cost basis in the Company’s financial statements. The estimated value of the Real Estate Assets reflected above does not necessarily represent the value the Company would receive or accept if the Real Estate Assets were marketed for sale. The market for commercial real estate can and does fluctuate and values are expected to change in the future. Further, the Estimated Per-Share NAV does not reflect a liquidity discount for the fact that the shares of common stock are not currently traded on a national securities exchange, a discount for the non-assumability or prepayment obligations associated with certain of the Company’s debt obligations and other costs that may be incurred, including any costs associated with the sale of assets.
As with any methodology used to estimate value, the methodologies employed to value the Real Estate Assets by Kroll, and used by the Advisor to make recommendations to the Board, were based upon a number of estimates and assumptions that may not be accurate or complete, including estimates and assumptions such as comparable sales, rental and operating expense data, capitalization or discount rates, and projections of future rent and expenses. Further, different parties using different assumptions and estimates could derive a different Estimated Per-Share NAV, which could be significantly different from this Estimated Per-Share NAV.
The Estimated Per-Share NAV does not reflect “enterprise value” which may include an adjustment for:
the large number of Real Estate Assets, given that some buyers may be willing to pay more for a large portfolio than they are willing to pay for each property in the portfolio separately;
any other intangible value associated with a going concern; or
the possibility that shares of common stock could trade at a premium or a discount to the Estimated Per-Share NAV if they were listed on a national securities exchange.
Limitations of the Estimated Per-Share NAV
The Estimated Per-Share NAV does not represent the: (i) the price at which shares of common stock would trade at on a national securities exchange or a third party would pay for the Company, (ii) the amount a stockholder would obtain if he or she tried to sell his or her shares of common stock or (iii) the amount stockholders would receive if the Company liquidated its assets and distributed the proceeds after paying all of its expenses and liabilities. Accordingly, with respect to the Estimated Per-Share NAV, the Company can give no assurance that:
a stockholder would be able to resell his or her shares of common stock at Estimated Per-Share NAV;



a stockholder would ultimately realize distributions per share of common stock equal to Estimated Per-Share NAV upon liquidation of the Company’s assets and settlement of its liabilities or a sale of the Company;
shares of common stock would trade at a price equal to or greater than Estimated Per-Share NAV if they were listed on a national securities exchange or that a third party would purchase the Company at a value per share of common stock equal to Estimated Per-Share NAV; or
the methodology used to establish the Estimated Per-Share NAV would be acceptable to the Financial Industry Regulatory Authority for use on customer account statements, or that the Estimated Per-Share NAV will satisfy the applicable annual valuation requirements under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and the Internal Revenue Code of 1986, as amended (the “Code”) with respect to employee benefit plans subject to ERISA and other retirement plans or accounts subject to Section 4975 of the Code.
Further, the Estimated Per-Share NAV was calculated as of a specific date, and the value of shares of common stock will fluctuate over time as a result of, among other things, developments related to individual assets, changes in the real estate and capital markets, acquisitions or dispositions of assets and the distribution of proceeds from the sale of real estate to stockholders.
Conclusion
The Estimated Per-Share NAV as of December 31, 2023 of $13.00 was unanimously adopted by the independent directors of the Board, who comprise a majority of the Board, on March 27, 2024. The independent directors of the Board based their conclusions on their review of the Advisor’s analysis and recommendation, the Kroll Report, estimates and calculations and the fundamentals of the Real Estate Assets. The Board is ultimately and solely responsible for the Estimated Per-Share NAV. Estimated Per-Share NAV was determined at a moment in time and will likely change over time as a result of changes to the value of individual assets as well as changes and developments in the real estate and capital markets, including changes in interest rates.
Forward-Looking Statements
Certain statements made in this Form 8-K are “forward-looking statements” (as defined in Section 21E of the Securities Exchange Act of 1934, as amended), which reflect the Company’s expectations regarding future events. Forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such forward-looking statements include, but are not limited to, market and other expectations, objectives and intentions, as well as any other statements that are not historical facts.
The Company's potential risks and uncertainties are presented in the section titled “Item 1-A — Risk Factors” disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities Exchange Commission (the “SEC”) on March 15, 2024 (as amended by that Amendment No. 1 on Form 10-K/A filed with the SEC on March 22, 2024) and all other filings with the SEC after that date. The Company disclaims any obligation to update and revise statements contained in these materials to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law. The following are some of the risks and uncertainties relating to the Company, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in forward-looking statements:
The Company’s operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market.
The Company’s property portfolio has a high concentration of properties located in Florida and Pennsylvania. The Company's properties may be adversely affected by economic cycles and risks inherent to those states.
The Company has not paid distributions on its common stock in cash since 2020, and there can be no assurance it will pay distributions on its common stock in cash in the future.
Inflation will have an adverse effect on the Company’s investments and its results of operations.
No public market currently exists, or may ever exist, for shares of the Company’s common stock, and its shares are, and may continue to be, illiquid.
The Company's real estate investments are concentrated in healthcare-related facilities, which may be negatively impacted by adverse trends in the healthcare industry.
The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of the Company’s tenants to make rent payments to the Company.
If a tenant or lease guarantor declares bankruptcy or becomes insolvent, the Company may be unable to collect balances due under relevant leases.



The Company assumes additional operating risks and is subject to additional regulation and liability because of its dependence on eligible independent contractors to manage some of its facilities.
Joint venture investments could be adversely affected by the Company’s lack of sole decision-making authority, its reliance on the financial condition of co-ventures and disputes between the Company and its co-ventures.
The Company may be unable to renew leases or re-lease space as leases expire.
The Company’ level of indebtedness may increase its business risks.
The Company’s financing arrangements have restrictive covenants, which may limit its ability to pursue strategic alternatives and react to changes in its business and industry or pay dividends.
The Company depends on the Advisor and the Property Manager to provide it with executive officers, key personnel and all services required for the Company to conduct its operations, and the Company’s operating performance may be impacted by any adverse changes in the financial health or reputation of the Advisor and the Property Manager.
All of the Company’s executive officers, some of its directors and the key real estate and other professionals assembles by the Advisor and Property Manager face conflicts of interest, related to their positions or interests in entities related to AR Global, which could hinder the Company’s ability to implement its business strategy.
The Company may terminate its advisory agreement in only limited circumstances, which may require payment of a termination fee.
The Estimated Per-Share NAV of the Company’s common stock is based on subjective judgments, assumptions and opinions about future events, and may not reflect the value that the Company’s stockholders might receive for their shares.
The stockholder rights plan adopted by the Company’s board of directors, the Company's classified board and other aspects of the Company’s corporate structure and Maryland law may discourage a third party from acquiring the Company in a manner that might result in a premium price to holders of the Company’s common stock.
The share ownership restrictions for REITs and the 9.8% share ownership limit in the Company’s charter may inhibit market activity in its shares of stock and restrict its business combination opportunities.
The Company’s failure to remain qualified as a REIT would subject it to U.S. federal income tax and potentially state and local taxes.
Complying with REIT requirements may force the Company to forgo or liquidate otherwise attractive investment opportunities.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 HEALTHCARE TRUST, INC. 
    
Date: March 27, 2024
By:/s/ Scott M. Lappetito 
  Scott. M. Lappetito
Chief Financial Officer, Treasurer and Secretary
 


EX-101.SCH 2 hct-20240327.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 hct-20240327_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 hct-20240327_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Series A Cumulative Redeemable Perpetual Preferred Stock Series A Cumulative Redeemable Perpetual Preferred Stock [Member] Series A Cumulative Redeemable Perpetual Preferred Stock Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Series B Cumulative Redeemable Perpetual Preferred Stock Series B Cumulative Redeemable Perpetual Preferred Stock [Member] Series B Cumulative Redeemable Perpetual Preferred Stock Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 hct-20240327_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover Page
Mar. 27, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 27, 2024
Entity Registrant Name Healthcare Trust, Inc.
Entity Incorporation, State or Country Code MD
Entity File Number 001-39153
Entity Tax Identification Number 38-3888962
Entity Address, Address Line One 222 Bellevue Ave.
Entity Address, City or Town Newport
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02840
City Area Code 212
Local Phone Number 415-6500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001561032
Series A Cumulative Redeemable Perpetual Preferred Stock  
Document Information [Line Items]  
Title of 12(b) Security 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share
Trading Symbol HTIA
Security Exchange Name NASDAQ
Series B Cumulative Redeemable Perpetual Preferred Stock  
Document Information [Line Items]  
Title of 12(b) Security 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share
Trading Symbol HTIBP
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.thehealthcarereit2.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hct-20240327.htm hct-20240327.xsd hct-20240327_def.xml hct-20240327_lab.xml hct-20240327_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hct-20240327.htm": { "nsprefix": "hct", "nsuri": "http://www.thehealthcarereit2.com/20240327", "dts": { "inline": { "local": [ "hct-20240327.htm" ] }, "schema": { "local": [ "hct-20240327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "hct-20240327_def.xml" ] }, "labelLink": { "local": [ "hct-20240327_lab.xml" ] }, "presentationLink": { "local": [ "hct-20240327_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.thehealthcarereit2.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20240327.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hct-20240327.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "hct_SeriesACumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20240327", "localname": "SeriesACumulativeRedeemablePerpetualPreferredStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Cumulative Redeemable Perpetual Preferred Stock", "label": "Series A Cumulative Redeemable Perpetual Preferred Stock [Member]", "documentation": "Series A Cumulative Redeemable Perpetual Preferred Stock" } } }, "auth_ref": [] }, "hct_SeriesBCumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.thehealthcarereit2.com/20240327", "localname": "SeriesBCumulativeRedeemablePerpetualPreferredStockMember", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Cumulative Redeemable Perpetual Preferred Stock", "label": "Series B Cumulative Redeemable Perpetual Preferred Stock [Member]", "documentation": "Series B Cumulative Redeemable Perpetual Preferred Stock" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001561032-24-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001561032-24-000009-xbrl.zip M4$L#!!0 ( $\Y?5BR :M\QSX -4Q @ 0 :&-T+3(P,C0P,S(W+FAT M;>U]:5/CR);H]_LK])CN:2K"%E[9:IF@**J;Z=H"Z-L3[\M$6DKC[)(EM1; M_>OG+)E:;!EL"K -FHBY75A2+B=/GGUY\U\W8\^ZDE&L O_M+VV[]8LE?2=P ME7_Y]I>C\^/3TU_^Z]V_WOR_9O-_WI]]LCX$3CJ6?F(=1U(DTK6N53*RDI&T M_@RB[^I*6-\\D0R#:-QL\F?'03B)U.4HL3JM3L^\9IY&ARW9V3]PVJUF;R"< M9J^U.VCNM]K=9G>OY^P/VX[HM&3C\O# /7#V]]I.\T#L=IJ]@\Y>\Z G#IJ= M0>?@H#?LN6Y_T' /V_#6_GYKK]7J[_>ZPSTQ=*7<[;4'_5:_VW&Z-.\H@3W# MOOWX\&80>>KMUBA)PL.=G>OK:QM_L8/H\J7""?S^DU<'ORZ:X9N[_S/YT_GSDB.17-Z$E?F7]$,L73LR^!J!Q[ MYUN MOIJD"<]*4YAW\\7L))'P8SP3D< IXUK[S=9^L]LNC%.]K=L&Z;2:K4ZSW3&# MI''S4H@P&V@HX@$-HA^45@[#?K\%[/AX(.(,(CG@*PGW]WAA^;5D5.&#>#Z2 HO&3DBDI%42<=V@C%NKM?J=O;HLT-/ MP/79DG[SC_.M=V_@???=F[%,A(4#->7?J;IZNW4<^ E;%)(2-.OS7VZU$ MWB0[M-B==__ZU[_>)"KQY#M81M/,\6:'?WNSPR,/ G?R[HVKKJPXF7CR[9:K MXM 3DT,_\"7,KVX.\449\3^5ZTJ?_@G/O\!UCI3#T]\D9W+X=LMI F;X8HPC M275X!!?>Q4O_T1.76Q;CP-LM0)K#H;J1;G,H/#PJY;[=&C8[_:UW'X\^G9^\ MV2G-L,2$)S[L;W(,,T;"._5=>?.[G&3C[VZ]:\']Z>^V 18SD^R4=QC)(1P2 MW*VXXEP0;0YCNH.P#(O0Z#"!TWB[%:MQZ"'ZT6^C"%=9/ +[)G;A?&BZ? X] M91RD$?U%U.50[Y36CSLUOTO:IOE+N?CW4,G(HB7)REM]?/I[>?O3'[\S/Y5' M#P$Z@6O^ G(3)1^ ?K_#_31;W28BU?2S;)GNG%?-$_.WF62GM.]J,'0>&PQZ M-_(2,9?_=&&RF]!3CDH^R_$ IG 5/"76MZ6IU.%Y EO";XX]$<=?A^=)X'P_ MNE'Q%M[!PW/8HXR/CM-Q"HQ.7_":C4":I\+X11D32I6]YJC<[ ME2O(@)4M=#..K[O1Q_?^)1W?3IDF[12XP0[P#&8<>*KJ+N'I?Y%VY=]H9C-6 M?G,D4<([['7LO7Z8O+Y6;C(Z;+=:/V_1J^_>Q*$ @CR(D&3ROWFSV$G0-/&BMO MG?]V^N77BZ]?&M8'^]@&':+?.UA\V8PYRD?" M,__Z.]VWJ]1N#>JUSFQZ]GGZW%Y32C#+( R^(9D(C]YN^S8EE] M8H^R3+CA9R=?+JRSDV]?SR[6?KG?_C@[_^,(UGOQU0+R= $TR&IWK:]G5KN_ M[;ZROGZT+GX[6?MM%"AK1E6/CB]P^>V#;J_&]D=:)LH[5C"TSF081(FU;?Z6 M B0>&2>6O$+;5$2/I?OJD/=EF8VM@J8N3TZ_D2!WPN)=6=]VX9?F&(88X6=- M5TR:$]A\4_J9>KSU[K.(G)'5V6N0Q:TFQ6MWT&S?.).7*D:K6O(%GICS \7J MM\R\9%U$:9PTK%/?L>]_CBLZMNV3&Y#A+=PA@R!A!]K!>S@P-[O=Q$U$U#V$M=,K-4S&W:P M,_M[9]_>V]VO?-2RVTO]WK'[^\M],6]1W:[=PZVLU:( 4@?MO5N'VB'(,_3A M?!%/WFYUM\S+H7#1TW+8"6^L-ASI+*)/'3*?[]-3N-9]*!R0K2 "5DP> S+, M' >IGT23X\ M,S;4^M'VD<@P"JYPG)RC]8BC33SANW-I8.)N&H1GZ$FK@IYL MWK8>!G$^*D_"RP/@71H)^F@O;#>[!^U^M\:"==_6PV#!A;@YU19AATA(&25V MM]YU]YO=_?W]@]T*/U !>'<08;J*P51%:0 MC&1D_95&*G:5@] CZRL(8JI(E5]M,);]X.5Y3L=^'(S'*D9/B(6TT^*;4A_N MLSC<4_O,/K>MDW'H!1,9T3TN$T;K2V"_FB5Y.Z0YS-.GUEY[VE3%_LAU(QG' M^C^?8+RVX5E[6^\ZG8[U7GJ>O$JE=70EUUFQ?U!X',,_OT87P74FV>]OO8,E MH:UN&@:-);P0I4F(_WV-OH$6H2BBBF98O#2"-%#&\E+D,=8_*@3$EK2"URN]]__L=^I[WW.K82ZTLSA7^C%0"% 9U M[M37&E@\:\X>!($W$$ N$B!:&>?H(N .]GJ]UP]KQM3$>JTP1 ,*=E*$E!6F M49PB=07Z?)8"I>EU^IK2(HD]!\D(/E2PCB,GL;;;>];QQS.KTVW9\.(R:FY- MV&K"5A.VQ0G;>4"AS3#E9Y"U0.#R%J5JO1=$U7(H66,-IEF2UNX)T!(*5.WD MQAD)_U*6:5H/K@^]69.UFJS59.UQR-JW2**LAAE:%*V,RF'T=3A$?7XQ\M9_ M0>0-H-5T"N"Z4WIK]]QF9WOP:C%BQ^_6Y*XF=S6Y>Q)R=QK'J8SN0?1V:Z)W M"]'KRF9OVUF,Z.EW%R%ZJS$09@'R3TM: ?9VB[%[F0#57L_N[>\^2"QHR^YW MEHLJG;>H=M]NMQXF:K9E'_1OCRI=F'?T[4[G=DA54GP0>-:*Y!\LIICEAB,V MXT21^NZ^$RX6)K$CTR#9/JF+L++!3!*3+.R'(P)WH) MZMW"#6KLV7A(1((3\2#PMN-E@J.>$QQ,/@8AA#0\"R[%]4C!+_G->6XA ME(L1D5OEK$[)6L;D9M+N#.B698+3WM:[/;N[U__9XFH#UI&5UQNP\H(#5E9Q MP,I*#EA4[ XI=XAIHH,$W(#G!_ MZ]UO%Z='-:@?X[H8,9F3WJ95$21(Y?2/]@'0;F#37T3LBK^M7[T 5!7KLXB^ MRYFPL6? QN\!YNXB5*G30JK4[N14Z?U&4*5G>DR5A*?3)L+S_EL-SGMB_;+$ MI=/Y$>(R1WN?$YBW&M7^U'?1BB&MP<1R**0*%/7O(.Q)2A"9BG=2L05+E+#A M2Y25+Z/@.AFA,23$&"@16ZXTWN M>_,R3 /G%&+.+^:JL$6E,VAV*L8JF55XT%XV*%I7\N\*P]ISP+]69W,R!\Y+ MEBNXR\*XO]!BE@V&-HO_E=9^S$M?T+;862 *9J%S6[NHQ=/A+1<(XUPK;Z.: M"3P:5B^ YNL/ ==%L+Q\&$7'P9*Y"Z(G)C#FQTIRPGY\9RTMT6F>6D>#7M MU6 MTH']V=#&A9!FJFA9&# P#R/)0M%,&;-)'%O[('#: MUE?B52=8W"6>>YQKNHT/$HX1#BP+,3X!^C2FVLD@:3?/47R&N1+K*([A?_^- M@O4:[I%&/%0)$%EG@5U_!3'R2LGK>^^DRF-4#*=N[Z\LG!H%QD$ M!)/TU41 MD,8@BJUM)(F8X]!IO7Z/C^G?[==$+JMKNI2^T2PT^PI90(@TFT/7A1N$B#2H M>3$N7:9 IG%Y,?(&DLF :_N:4A/U=S7R(84GWI'A'G",)JENP!VP(@OB'BMU MVWH]E7AZ]._BKG#(PK(IN0,]9P&>"6B,MO6'<8\!\\K7VRA^"7QFX*D87D'6 M.6=6-%"*Q/*DB!-\3?@^:J@#$:O8GH&N=>0"JX-#:5B?/AV79OL%9N&')>#K M#\SF&A9H0 XJQ[ J8G5SEI6([Y1UX ./!.#'L$-.K*:L!:%BX<7S( 54WL,3 M07F #@!PB*RR?!HH*P CAFUZ(#D(L](S_.J$OR*2H=<,("&-#X4&8%[X36%_ M,U_%V3FRW1M5#2?2N@W5!%8\0U%!XB%^N6YT7@JY#3 MMO#": "3$"*O8XT2V?LQW"@8@P48 &,,,HXSN7U@VC%^P;*3B ,?]3%XDH%\ M_@X*^(JY1Y3(P2LM?I/?;CT@76PK]1@;X%J.Q7>ITTE\ +&[$+4_^O?"4T4X M"0R5Y##,EJ[\,$V*R5,*4 C!:X8PUYT@95)I-%*6#OMV6#6L09K 3DF S=<& M5\E5L1-)?+&1H;\N/3 4M)M91>P1.?KKRV^Q*5@ZAQ@RN52-^ ^A20,I,!$H+D+^Q^"M $T_Y>E@IZ#)JK%DD M)HI= 4;?PD<$3?-!.EQ!NMLF6'5+S.#?&?9C!;Z,4,J_D>4 H5_E$?_4[MJ8 M=+B&1PLT;960N85+PXDSW*S8*-451&\.!1Y*SR-&I&E?Q [38<:7*-Z *T[B ML+]'P(1)\+"VB<)&@)K?_>#:1^3[D Z'UG^*<)59Y$6^62&- M(==D>:4L@Q""X#?,Z0IO>TH,E$>&2^;P&;)H1,F,*P91K&M BK4\;^R_XAK1 M(U<!F&!!F0$ CNBH94Q:+^P$&+VM#"R/-#;M$:>19 GO?SD8>T7*:(JP1B MN]UIM+J]1J??7DM HJ-]E?"))+&]HGG'"M*$_ 94N*,D6'/TO9&NF1?._W2, M7@@V8J$=Q9A>;K6\W#9?F10Q@ODN>B\=3T2D(+B6PL!XU\(Z6J1D S4B@]BT MO>:7LDT+'@$:7([F3,VZLAO ,.BWT0OA$A(D+9C5E!<3B@E1&85Q>(%')?S@ MWT@&%UY8G YBT%$D>VSFG03F R#0""7[B(5^P>SQM34*KN455IHQ2R!#&[T%X$:K!6X0QG DTGU<8(R!DEAY M!"1[!$U27#.ZU'A5K- F00*PRQB,*"V49RB8;:Y ),(T@RJ TCH0=;1O#:2I M=(PP\0-8DH=@,"86;LDGG]C(\G21"S/FZSOUNT6M"YFQB@SJ$9K8C<&J:$_C MP;*FA[/2NYX/KB,C'N%-"?7@)Y&0D)]CZG\+/Q6@FU!#3".HX/3\,A 8R9B' MH3@ 4'D3LM(*5VD@,5S0G7/9R-\=&UBI(\"."Y/([X!!-A_2E:!VJY M< VM2U@\;+]LT(9IV-":XV^V91XG<*1T6?&!R4?B"F\\7%_ 7$981ND8?DVN M\<$'\N;KDP&9$9H*J,"Y=L2D<^54;@[?@5L"'E&FE]F"8IC()A U[A0IFK MBIA$U/$I0+TV[LYS29$85VB?/ (N.HG5_1W5:XY3YN(!^DA-WD2H0TY(XPJN M&]98N6&@L-<#W.41C&"1J&$J;!FKB"-"@O$_3&(B\K?A)^A8(*&0?R+1,#.9 M -=-O81IZ2VF7IXEL]K^U.Y@]&J36,5N*P]>9>DT6S'AN4CTYTBY\J" OHI 6"*9M9R4#Q*Q+EA$Q+S'G8%\4C &( M,?"E)&J4+">99#GW)M"%P2&'43 FB4<;,C51K]PPNU:#N"2+:)$BCL"3AWUD:E 5_; M9#/6E9.8.[G4"JL1[+7VELV8W6W;N_T'RYCM/E#&;,O>[58_6NFB>OL/TV?F M@2'5J0LW+)/RL%@*\QIVR3A#ZL0P"(;\WW),X(_E-CW3X]ZLW+H%4>%3<+T M7!;:\,L!VF06Q9RO\&_ETKZGG&)#(:R-QS>MNVU(S\L)']#&]@B&'/7 MEHO8PJ]GLSS5R+(D<>\L*G#5RO!SD M.-A]H!M57XO%&N:G;L_5G_%@8FX0!; M[[;;4PWP'LH(L]!EKT"##;GL>_;^/4T/&W_9:^2X"U[[=K=&CAHYYB''BZ4< M"_6;F!^[I/??1-'@L-/C8*D[ IJ:CQ'1M%B)I )K??+9R[#:MW<)"AY1-.AO2M5S@$@8;[MFMSL_WCY)= MFY#8;Q@.'C_+*-AC4Z$DR0N43(?B514L:>CXU;STQFR1F H4$MG#B^ MB"AOHI@7W5@LIS?;8S$-*,_[6" MZC!BP<48T\(P$05;GH$$SV+#\.#!$G.I>F+0,2LUR@I"V>QU$WPN-GH!TY3!U/\\*B4Z_ ME('(-%XQS"\_%XZ -_4Y1@6.Q-LSU;Y"+ /G(Y G4D0Q(5N,/+F *&HV?S!/ MG)U;EHO$1L!($9F/BK@U5;@.TZ(TW"T'[B5<)RPY(IGWQE@"T2E(GX!B:03" MHQ]P8B^>"LF1^C"0FB""L>4,I^>+D+6:IVS9;%28(90.YAQ@\3&JI6I*9<+Q M^U2AA,%':$M!\;$3J0$F+4C,X^,\Z-)K!$LM5%@.J' "TY#3R('#T+F"F+0: M.+K*'0S W+Y8/R671,QJ#7YFB=&<-0% Y 1-K* '2XJ9*E!Q%DQN%85:A@7( M/TM*^BU B1)Y!EY%H I\YPQ@LJ1)G7B*V.!CEJ7O-C(2:3!37Q--01LF7X1/ MBC\9"U"!N+86INQQB@A.N*U>562U&@S#O_DH*>7:*^6&3@N*LS2_89:FB\3 M:$7$*:26ADQE06<+@58&D:Y*.,0\4!(W#169VF/&A(%XZP(B.6[A;SA.@_/K M,0@3^3IR"F#Q.LE7I^(G02//'H8/8&:X#W3O9E=A &\.(E]5! %B)8D?[S; MLW>$B 8?T=*;AS.\QCI5PA0E*@U:O#K6GR/ER9E%WVM>OL6&1.,PB%7\M]XQ MPAEUF'R( M39;X#M+E2\&RA^/JDGO"D(J3.5(AB7E&-(BTO2L%DQM+I MH+EX$8XF,7H8&L66!G"+)5S;8(Q-+$"N!QD&=@#GX]3'ORX7%>OSI.XD:T.H M#8IPT&,I8A0+G#2*D-OJ)ZBIDK$2^'V<8K4!3L>68ZH!;2JWZ'8;H4A0H<^L MC5CS1+L6?)YPKK&U1I$54P@T.I=[E*!PFM4%+!(.M$Y(KEP2!6,2M0NTI"08 M%HOZ&#)B>2 IHGLG'EE#=,+D8C"6F>>:9G$Z#IF;4'44]/VHJQ3ZMITK:<91T<0):3+N'*0-"P']"&5(+FIW1FU.V,-W1E4 M]G3CR=!&<[!&NY MFL"\,S]$@PY-F\7UX>HYZ4C9!)?;V8=I1"]1&1KR;L2R\ 49I[A4)(BTQ=B6 M:A&\V*#MW+/X MCXR"6\LEOV)>M'WRJEJ8K6796I9]PN 5K#B]<:5AX<5"4Y,JNU5*OK%G_/!MJM_!Y(F;S*+#\ODV*JNR?2YL-2[EI<9 Y98Y+$'M!ZN4^5* MJQZ^*I5&-]Y5]CZY.IRG<0=G $PAE6,NPBKJX6;*_B(OI;@DC)WQ)U/L%;E= M::'E+GZ%DHFWW!%>,,#=EX6V?H6@62K2J Q?*\30I=0V\@_[W"Y(.\)Q)+7 M++0M!O''!QD RZ(C'50$?$"_"U>)2G>])K-E=H[K'JMQH5\KMP/5ZC^9"Y!)P4JQJV#6@30W_NN( M$:XAKV.AJ%8NB?&^5C2(PP']H%FDZ,Y M #*,>7"X2H%W)=U#LCA,Q<$7<*?@+#,>_!EJH!5/%.Z=41"PTZUPQ@L6XB:; M:3[?1H5F+#A>@QC=H[L*0U:*AMWAMS^FMX_PM Z6, MIB B&LJ$'Y88V8Q:@LA/5#2Q/*W).-(KV'BN\<;IR$D=(AUI([\$@AMEP8Z% MNZ"GQ*LH+B.I!?"8. @&5W,+;-P"O5XQOR;3&0C4E-4IDXE)K4/.C+'U%,.F M666B^:3.$2"S&7%E[@73('*@@S'Y5>IDP]UG8/$Z4@>[TPMNRS+O0S2^_TTM MS$E3XCUE:T*6\P+PE^WY?H*Q2-.Q]*4F] YH"+S+38[B"F@#JS6>CH6AC13A7/H*C36_ M!2RL?LNZ%#0H(K^4U;%(KR9F@OCIYZ_O,SGR63.Q\W1,J3( JQ?%R>X2\9#X MM_?V*A,G[O1>TL?]N=_.4A>=I80$9/Z$TY=$6Q*Q1=D<'Q)^-Y<5\^?75;GR MSY@T<>,S-R,F4]YJ.KG>+92%==%;3[^ZL7W'.+AN]6E7?MI%;CXDM3%+VV?=!>=O+'!U1_[_;V1:M84V?_H9I//=CAM>S^07_-%M6W]^X U(+-B.YH MI'+K:P<;VLQI04_22^MQ-=>&^>P+D?);-@&Z1D>M>797PFJ\7/ ' M-@Q:L[:('VG7]<.]NC8,>K-&F1IZBT-OKFGJX;G09@#D(@"*]6-UU!U'R@WK M63+/07*O,L)3^[_K)LW[?B/YX9QV/+W=&I(/ LE.#<>'*95?P_%A;G8-QP=J M?+S?:7<6Z7S\]-#<,%"V^[L_)K]L8,^U^8ZN1^N7]&,07$.\Z=Z/EKU(6+6[ M-:R>@K2_2(#=3\:M056#ZC90]?:7D0J,B]L/?#D?-/5;F_;6 QFSJ,W1WDRS MG[63"V>M>:M1*G142!<@YP8IQIB8O3\;K6-O'4P*+P#._1K,+\0^]ORA?#\M MJH;RYMG,JZ'\?$#E!HJC$.0M0L]@F!(K [FAH'RN>#7".:=JHQ:D3V2)VUE79ZF&FID MF?'3=<+*8Q=*R]Q2#99SN.<5+Z'4@JL<$ES.!R;XJ=VU6RU*[_JI9?RK7/)0^O\M?4J8_+U M"CMTR.M5UBDQY2EBG?S/IT&%FW6O0\ XS!Q/8]--B=,M#-3SW'>Y2'FI4KU& MX3FI5ZK15HE8XHKS8@IEI^C@VZU^H]]K-W;;G=LK9.#+G)&2%Z#S)GF*298_ MP$4RL1 &71)"YQM:D#>Q=G^FZE,S!=UX[_ T^Q3K7,[6?5,Q)2QF5]_TQ1A3 M564- $[9P1'R&Y+5%=$7UI6)4%X.1TY'X'*9SY'H'L46D3R7L;-!3=T0L%SM MS'>Y 5:.KW/P\%I1,Q)LM$=-2#C-NF'E5:3FT36JT^%0A[IBT:G9PFJ%4S?8 M$ .:27_>FG &W:..&JEP,QW$/?V"V>-K:Q1<2Z 8C6P)5!^"WAH%'A9_P@U2 M7K/2%#468TZ, EJ)H$F*:_;A=$S1,4(CM(+D>;NBM%">(6,E>=.I*H#2.K"@ MAL9FJ@F/,/$#G5J<=6VBEF5#&3UL)N,&Y>CT6P^5YM'O+I>J#-%S<=X7QKM>M.U^YTJOGXP^S?!&LM#(?E M7;P/BKDO'7DW#W_W#AX8?VL4KE'X*5&X9^^W:Q2N47BC4;A3HW"-PIN,PGV[ MTUU#%'[J[-F5:>*Z#-G&ZN"=']'!%_& =98[]$IZLW[WKF4?["]Y[:HQ_-&8 M0WTV]=G49U.?37TVS^1LEM54'NAL7HQ/Y0,VGB/)*>M>(9)B0]$-E.ZZC^1A M6>BV52#"QMRV3O]^2M4:J/[UV=1G4Y]-?3;UV6S0V73OZ0VL[70+@KC0(IWR MX@;))LISO=I:=Y_#WVX#]=M]5:NU]<'4!U,?3'TP]<$\EX-Y,>8Y=K1^RBMO M;*+\UJ_MZ6RV[M\35JO76^ESJDY_+B[&]G<-G,-J1 M]2V20QEA8;)SK*&S>0*<,.VK766I]+?2[UN=3G4I_+(YS+7FU\ M>V0)[OVT!+>)-KB]V@9WSQNVOP3EJW77^ESJGMXT^D V. M0=Q=\RQIW2E@^>FO[P %KO&]_NV*U[)C4]'(Q6I([7 MMZ2^)0O?DOX]TS+K6U+?DI=R2[KV;JN^)0^\P?J*+ Z=M;\?K2>_'_7EJ"_' M1ER.WB9>CA]KEFFF;R*24C.SNQJ>-5?8\:Q0*KHX_=QC>9IUE6&X:W>I0\(% M-Z_,&X?-:519:*87-U;9\C#KCWF/;IN1''K4H W0%/N>Y4W>X)N.W?V9QMJU M=W\VO>JH3YRDEF[;ZA7]*2XO(WF)HSHBBB8 T;N 1Z4YG""F87[JV+O60'F> M"OP&S;>M],B ''%L >9_AQD]W8LP$?ZEPCM::./)XW1MG2(]YM%LZS@=I^Q< MM-0X%"K"%F_8QBVZQ(]\:B:'-Q3_NO:Q)5^I\:*5]5RD;G+P_*?.GGU0FH77 M3(T-&9KPUK7"#G+P ^Q]RPFWD0NHW";N%Q]05DCI*9KU/81 % MYS0.7.G%V+_.JT0ON%:: $K^@ZO M]SZH"*_7<7GBSS(9!0;5UI PWM5L:Q4G_)!X^^3M% ]V[=Y!>]ENBKMMN]MY MH(YU^_9!:[DN@;?T&^SO/^^ AVNB5W#@':R[%+]V_J$(U6,.27 M>OCF,)NQ^3_I#^F^&40[[XY0F)J"Q5.'FJT"L:>XW!DPQWMY)^]1X'AMT*,: M,KMVI_\S-6UO=UY;^_C7CT!FP2OT,B"[U_YY]J8]KEZ]UD(NG- 86P)62[NH MJH!4XP!6)$\C /-<\.!8Q"/K(ZK6M?Q;R[\+R(?] [O57U8XG?=[K[7[($)K M!^3?W>6&>AI)NG.[>+^<)+W6<7";U]N[N4;JP_[B&846V8R<_3PB8-7OQ0JP*M_!,Q !J5)K.?,"3> M$?^>RN,K_.\HRL632]D<1%)\;XHA /A0>-=B$N/9%54@T$>F5K_LQ,_7]]ZI M]+VOTL5^ZCM>ZFK#16[1P(\ME!1&,A3 6>5-*/U86TL"*EPGC-_:Q?/%!021YQ60M\P*TD<%) M/_+Z:,1#DNF=!0#V)0!TV;6:5KDZ]L?L;ISZ@.LI78Z51J@DP:V7V0E\$FG% MO)N-H*\:X,CW4WCQ3(9!E& XQ\<@&EOM5O/W1A8?P;H1@,7-&\2H'"Z6@B.6 M;#1%ZV6,5U1D-E)-):PAVBT%*%V36%'@"-E(@4XXI5?B+!@CGPT)@XKSCW64 M"%,_V'H2"2?!;> B,@-K_CU0'44$T]A40W@4D,D6Z$4:J6320%OJM?0\LJD. MX)BNR+['IMLF9L\C^H9I4AI,H<@"=(<,P9:31E>:YJEQ".3+M:X"Y/P<8F,# M-EEX1Q**>7$B"?\L0)@I(\&T08$G,$\0P<'0J<)4C ,%ND9&9X?E8B2G52<< M HK["6*#'_BP<7@/T-&15J3B[UGDT\P##40^PB@4%.'S8NAHKZ:C-1U]:#J: MA?--?SR&;RY!3(<;BNZD4$R(]ER+N.!$6HBNL@C%="JG&+>38HJ98P*GJ;(6 MP;+U(96.E$3:@&%Y5JS@: 20FTG(8M@@B"*60$%$0^LJP$("+-PQ-0\#)[U 88$H@@Q;C"8B^R!CQR1!IS%%^)#&?,97:" M*Q%-> O.")=)QWG^]>/9BR%L_;4C;(^JRFCFF-\I"C1UG C]K)F2LITS=#'F M]UVXK8!_I+C#JYK_O=(:D&MJ $4P55'_@9L&JM$@Y9!4/>F]]9IB>&ZMW!0J M3ZZ1I[L:J9^TX.>BO _YB?(5RH+>!*3V.&51(@O5[K3:!T"TQQS:($&9CXGG M(9)ZZN\4^2(*JB5FUFT<[.TUVKV>%8^ @*]O1,):GHF1O]NM5@.F D:)P>H MPHK5_L'/@+4G\!E1J_6%]OK%?S#C%R5,#@FX)-E0_D/?AC, 88=Q^<50UKV- MHZPSA?C6DK)^=9* "6NG?0_"NMMEHK 9A'6]CF2CR>13DJK'HSES;0@SD2D$ MBD^@52:")6=]!3@'ZR@,(Z%BX<7WI\=W4-\5$M^+7+&IT V*&6Z@)#F@7,#U M&@$BH"%B7C+;O(3+2)J\NBS@-<[2Y724*JDZCH+UP!>#E!03E%)BZ7D4-:N5 M_SSOK\&K9//$M>+7X$MT^J"ZE?V&0\BH8?E2D4MH(/%7M@W@]AT 0^K%B.VH M^Z<3"VV: 7W'2E1N#KDSF'8L)FA/:5BCX!I@"M-FA!<-M:BYE0)S<:Y!$'SG MOVP>LI#<2,8)_@YH/.ILBHT2K) )-.+ L;N -<)^ ;B.C&,1 :86=IRC1V%!UG60>JC$.A)M^@ 4(UEF%AJ[K1D M+&*P:1<>W$NMX6IHDE\O&(]E1%LL9' "U'R.G\;%#KT4K?8)*^7Z/!'*F5, MCI[M- :0PS1)@=99'],($8A-:R<9S+[)J'F.U-#Z49!L,@%YI@@BO!0!.DQF;.4[G6!1=;.]:^C[S MPR)Z:@*#5V1 ;@;G9R;PP)GCU.QX_0$Q>7W)\E&LF3 8DS1 M]C#QY22+]<\(KS9'4OIX]AX=_3CT@@F_G5^]BCME4I4Y#=J0XX(AEAU5W]$6 M2A?+=_6I:OON^T!$<'H%0VX:,D:FI->C1TTOES%A)F]:$TO$!B !*7FS^!J' MGL34ZQPSYH\4I\X(92W\2D0<'@^($C?(3 ;;)B0$>@JKQX'8_&;!9D1C.M<" M)B\G63!P@![_!5?9R A,#VAX>FPL>@4*X:HAB4V)L>%I0WK^>W$+-$BV08?( M(_D1)=U?\\DE97JF+98@U MDK).ZS7%A(61BO5%HY_;KS6@$6T9,Y&)%!RH2&(?*M^CN[O>VCN!9/?UNMCU MVSV;M K2;;%*1($*5=6QN(3+Y3,5BH.Q9,$Q-KS)B(Y Z8 MHJ=,$OL4>FST M#0T#3R$A%"0D3+286_H./Z&@ BW038Q$D7\?2R1:B?0FKVO$627B(,=E4:50 MJ809Z+0L(JS+ $_9"4 MCOS7P#;JLUOUI0^#.%9:H.5K72U,,YB%&,MR'01>XN-Z9=$A8(ZP(ORW% Q?-H/Y_Q\5OE):*A@44).#<29Z/*) -J4\M!:Z6F5=@-BJ9R-,IOF)! M3!9SE:[YTEJ=C5$C^DH1/?488\D2B[8-.1T@9!!^!M_EWQ3/',SE0DXEU#4 M)>SD0<5G-X*VX[&B@=UF'NS_.U^K=JI&Q;.0N&<.!HZMX=*NJ MEG-_\C(9&0 _*0:*NW 6T<0ZDY=8>#2 ?QZE,"5F:9 DC4&_@#,.O!:,990E M0.2^M$:&H+>FQ%A&ERD8\#S:.83MO&C M63_1CV$'#MJQSOG>P.H=HK?M@[T>99D(-.##:K:UB?/D[/3\2-LU7V4!8:=H M^/0II/Q*^BE>)5?R./N[Y7'P=3T6OI0--2U-2[/8@?3E4"56Z DRVP_^TF_0 M4@J^HBC?%;\;1'E(;>&[<[;)6[V#O7[./MP?":!:7]US(>=.7OG47M$U=Q?BK6&+9A7$AK@$8.D 1\U4,<#Q8L/ M#_W\EW 77$ @+P@9=4U ,QP:0%)=*1?QW.1F%J+B*4"@X+KE?%#RT6A'+[ID M'+@5+"+'VF5C1.8X]P]FVRP*/_@X4QNS"&\C?Q1G1G6WH+,^ ]O-<8 ^"XQS M>([WXS;;S.9%8LU9[E.MZB?J6T'D) 46J<9!&H,Z(=P@3'(_,1YZ*.GDX9)A MP>0@RLR"QCL\"L@S2[XT 7?X+V:IY;>PMK( 8ZAT-DC*/1,6M%=LVCO,T?$ M.!F6FXP*S" 7'S8W)'&(O>//?MK7RAD"Q+3'$U'Y$UK\@@%B7]>4! @6F4 M\[ >E/L_?;DL9O9!= U8T?P4!-]QL^>9D/D<2?>QCBHJY#N.4<,DI("+04F- M^\W?R<6J1*HP$Q6Q@ RI(>D=[!OBQ,4=6XZ7UBZIAP(@KGG<$P4,JX%H"#F?'9A M8#4?N+9UCN$V\U\P@1$-"P2N+'+-0[<1R7\-$Z^7;Z$(-F %)-ZK+*/=ISQR M>E0@)+FWMC U&P?TE( X !@LZ4,P>I[A8H4HWE^*.?>$-!S75<:;"+TFY)WB MDR;I5]^,1"78*$-?L%. JM5N'F55G,XP/_\CHYNY8Z7<\""-;DE(SIC71 HX M<](AYP@_0^45P_ZJKBEL>JQBBMDM*J+G)\>9'FID"JO=9W&"*()17P?:2WR$ M?Q,C_!+85KNTY)VCF:6<'.?C=CH\+FO/Y';B*ZDP!B0N?\4N*IH2E3!F_<9. M16 4:JSQ.@N@Q%N;AJ[AABC%Q+*(\:5;R]F;YGK'[.A@:L50*\7-L603.!Q4 MRN']*.MQ%#:B!Q,L"LC+>;TF9GD\G2$PF:" M,J3<6R,%P1K3USSEO-46^IQ M@B8+38WGX2S[33BHIN3.%!Z0KO1R1-<=P3]GA,8L<:PT62]',$O7:#X]K!V! M*S4=7E0<]"SN(BH*.&M'*S>@ OC!6#GZUF46P>P>(#Z-Q)4._P/,C[E/D9.8 M*@!%298YWD.E]=68\&"8D(7EY?%X(U)SJ D7A7=AE9^"X[D6& _@;^AW_#<5$U4#[7DQE@*HW'81LU8JP+L_@E+DF)I:O-):FT M^,%RQDBBPN/ HZ9QI^4UIAJ%U!1D&=C64UVA:,%B*8L6AL8D@(IN9G3-!T;C M+;G!:R19.9)4G HZ">#G*\ZQO60G+]]X'Q8#.C9IZ_H1*_D%U9V(#!6YJGK1 MPXZM0'6 9DD_)AV?ZCUY^$\,[>' X/RQHX-XR2&@44GY64YI-?U*I$\9WGEJ M(:7(3;0!KZ3AUTBX6CD%(P?XO! 5N(OO92I #DW0Z2X=C[C.0/C?HS1,'$HD M'J#[C-PR,9JR_:0<,:WI4^J;,!QL683RSD!X7+,/2Z!QI M0.7F%L]/4MT@T M=<1M?2U6HNV1.14%+UU=%YAYP;B462-5*6JI\').@$L9"I.LRJ0.F#4.<(=" MT"0<%[F#BYYQ4X^8?$%(7'VL[&GLJSA(+BS4A'6E&/3?U.L=:6,:E<6^+(.[ MVC)4Q5 ]X5#59(P60)JLT"?2!-Y*)G83P=C0BB)@F$8B,@=DX8^ /8R4' /6 MU(O+TF["%,,=!C*YEK*DF&8J2.&C&KW6AD#-L%N0MU!2)(;*(F"3&3NLWJ$8 M#_U,WH2J-A6MSU'J"P_' UJ=CK.1 R ,/KK:=$6"B(Y2406E6-$3XD+U,:[9 M,6;%F*9J5[,UT'0ZP>BR]L*V%^!J)* M*3/M+N#4:+U2M#[B;.WJ<+I9%"TJ-'DPL#E;1.#I$%*.R0'T'TJ*%\+(& Q, M'0_0N3I5\8I\N-.W9XB2$2#XT%,.NUE,P&FCF-C D<:%1(0H>X]0%D.S\H 6 M_N;HS/K5"P;"*]=P&JGIQ@5YE$I.\+'9"V?)E(BX9@"U^6Q]Z#72-=W>/6'Y M3##" 6V[C*0T@=B![TVR6$E'14XZQFJR3MF^K^FPE17L8T,=#X^4;RAKP7WU MAS\O%G\!SQY:C++6*-ITA'3PK]2]-(V:ILK'!:'R^8]!D";EF./<*5@L=99' M[6LZ(=6@90QF%9(]S*$:Y8"2#"]V-*GYS.VID^Y 'EGV"? M-<-/2R9[;)GC ;:I(1:!X9>+[15#J9EB-5+K1F+(E3"/,&*F_%E$$X],GN*: M$)/K+F%7\*GL;HJXI(2_R+11,U15^910!,*J#JPU&&H\4GEM)TY3!YYID'F! M2UAC].HQFA/VK^&$XY$*<\48"1U2H+.3TXM<_#NP]W^>^4;KRM7A-*!11(F, MM/UDI 8JJ\XLD.0J+ME7B+% 4RN7AB&%FM=3%L B0:&%0XW:[KX. MCALD=W$ JT,&-U2"8UE$D*&*8+B%@?#B*;"A_V.3U,4NW9M&T2O[P$J.7<2B,F793ZF[ ME5U&U&R7,LBX&2,6M&9EB!BM' EO:,19BA71+V#4=(KM)VDX[?W\1]X2\WC? M$UHD<9A+S62W-()U8I$!3X2Q/#3_>(W>54],#I5/T*:/7L]R@2M,'0#^H6>A M"?EQ?MGL%E^X)(+_=\W,^K$-CW9F?X<;>[!W4/FH9;SL$+@89G H>^-NM[E9. XF!'';"&ZM=/FKD*=,'PV?R]+>S MQ>P6\R@SI$W<\J9VUWQ3,W26-O7;R=&GB]^.C\Y.K(NS/\XO&M;IEV-[[B:? MSHM?@!-Y-!ZHVX._<#_DHYA%(=B F'A9W(("VFV MMRQ?C&%-KE2''P*'VJ)_@Q<#]\1W<8 MBSRQR=LM=9,3PF=V2G7C'.G=@!=9G MV_HDPE F*@F>V29K/OM\-Z55+-3)8$\8$:MM1456S"(LGNHJ@V)>TCS#LYI0/,M>U'B>Y5,\/9W1 M>9-34F3PZZHJ64GGISG%)7E1X%E9G.)R1DIG&5(:VT!'D M2I.FVIA%TEK;5VFZ7J\GZ^E$Z55:9%F>?GAW<1V@R0XKN+P]0&]J+2)^FOKC MFAB(\);: [2[AA:(L"TE&C1P6TRHZE)?=S8M3B/-.^5?"<.EL432SV&8U=A^ MZL'DXR1WGOIS'RC#68Z+/$'$6LWKP<(;UXO7T)!!N&0'^<] !&\X,-=H ;Z5 M!X![QY;H%=@_20>F)Q2.JG1Y@I#O!.]ZI2V2CYPTQ-0A^<'@%2&]ITX3M.W< MA:+$!D%ZM''P4.LH)P5A3;1@;YEL#$O2)S.X)X:\+,MTX[L[GL%HEP(>^T>< M%WB:'Q'V2^U^?FSWAB/O1^2P5_9Q.43>=^8PJN O:>$I9G@WSTPC.#) )RMU MES+@S]'A0[A_&%$>D5+9P/>6G:WON6S4UN!,_OZJ>(E7T,0)\6@0C2@U?%5$ M4ZW$$[).>ZUZT):#N3_$@H-60^/8U.+XZ_W8:YBX1"+BD?]#(?AC%P",FR6A MW(M]/=&%;\DB,:X- K8W]!\NGT%S;/F.PB7_/Q0O2'UL\8X"XLBZ/?'&G2/. M%LFY;-\/9I*?2+LE M(/3!">'C-6BGE%?G0Q>2O7,-9>!F82W@$G0/UBT(ETXVH#6P:ZOH[3OH:M!N MXZB-U<2O1%8/KI5^V"Z2;_%OV%M:ER4N:*W01IL4&'6MR\'EQP;@?_ M]H=60[](MG!NH7.KS!;^>8^JF.H(EV_=H?>TG]GCM_'[#[Z-;_'WI.L6JTTWJY2^7BW+R!9JVJ*M7 M>VR?[DV@\G4HJOFKO3]/?R-Z[Y?7+UZ\_ V7"ZBZR6$#MH,P MN2BZLTEW!I._ZN9S\<5.CDO;Q;I9$/)Z^-IA?7[5%/.S;L(IE^MAZ[/- 06N MC6>42&<]D31S1%,FB,BEUY%YRRG\:WY@@O$Z9YX8FW$B#<^)D=80[K@Q,LH0 ME!LF+8OJ\T'_XFP+$W2O:H>/K_;.NN[\8#J]N+C8OW1-N5\W\RFG5$S7H_=6 MPR\WQE^(830SQDR'LU^'ML6V@3@MF_[]X?V)/X.%)475=K;R-P;0?.B^?O$V M&C6]/HE#V^*@';[_OO:V&PAZU(7)@R/Z3V0]C/2'".-$L/W+-NR]?C&97$?. M-KZI2_@$<;)Z^^>GHTVD1=5-0[&8KL9,;5DBXF&&[NH<7NVUQ>*\A/6QLP;B M@^C7+O>@5 _GG_ULTV1,9PBD\4L'!(]"U:?XB!BWS9Z.^>M<)$"TR[(;$?'F MW*/BK1>V&#/ &U./@':8B"Q@X: 9$^J=>6_A7(.\C["?$HOF&=BR._.V@0:* MCN_[>C$=@![66)./[1R^ Z3O@7!)!<\',#??O04$&2^JHB\B[_'C:H+>5"HD MN.R@"G!=0M;6RMK?&53V!:S^&O'2.BB'H[, Q6S=4XZJOF_8%4@XZF#1SB)W M--B(QL^^#SR/..9W62M76=!"WY_7G^9HAVDCHO^31\N<^K%L(K_:Z9@DW M!^NJP^Q^5T)O&R\^F/=OGIL3RY;,K3V?G72HF_J)#DO;MA_C25?[SV\NBW9& MO=;>Y8I(Y?%%YBAQHO%$*2-9#%QF+'PC,:)MW4#6RM)U=D#9M>LC-VGR*)@1 M<^4;;?C1W'D&S?6/"/>VY$G,@]MXW@[]X[L0S>[I@I$281/-B!GPH*BYX7]D MNNH?$NN?DP7@G=*,*I(!"YCMCA+##2>2:N]^#]E_XY$_!^2_Y00CT@Z M2K79"30%M&\.EXLE+I2++R@/ ^ :#^O<,33GT"UM>8RL0M- &#!_&%3E+"I+ M7:2<<*&RO@@"01<$\3D'8< Q'^,CRC#%_I@)L4V%;V9#*F_U3P[Z9J+0]$3Y M]>F8LXP::JTC"-D2F4F!F$,@(*/PN;<2D7]WHCS=_@XDR@\.^H@5Y;9L.L6Q M,Z45@\PY8K4V1'+,6IT933+A(1C# XO9*(N+WMK/H_J'+RV>'+P1K_;;.##+ MBCJ\J\);;(6]_N!"9 *5+D/AJR1*X!PL,5ZH8**FWKE1V+QC=H=H?7XX1[Y( MWU5=T5U]@GG1=HVMNC_L F9&J*BXS0DP*] [7-=8K%PD:L:ESJW5CB?1N\WJ M#K";',Q-5KYOSNAF<'*3L8;VLNN;JL XPRZ-1,6:!&*US(@V6%>VT M)M0(Q[F-&>=IE_)W@-@9ZL<+]68FB/1,^*THX8_EH MRGV=&A(P(PU$7^ P% M9 R&1-0+W*H@!94CT'YC<6VLNC@&X6L;B^$[<")J2RA@E- M&!YSD;C^A#??FQ. MZXM^$2F"I8&2&'']*(VVQ/(H"<^ILTQIBJN\\9B^,;QK/#\SI)LLYZ.Q/&B& MC\UQ4W\I*@\S&7-9-'EG_KULL3J;YG?=?X3@GN M)NEZ--*/Z[:SY7^*\T$E9M%PR#DGF74210487"\X0%3CBW$)RT W92EX7',%;S#]C[F\*6LQ",E+TW(8N<2(>U MQ$;(B%99X(;BW\9MJ*>QNVES!ZA-#.067I/VLXX;Z+,,4,8-=TGZ1_V:CS'V MFS)9A)P)+""YZV^-"NP05**REX(Z7,SQ*'P2OP_;W@&>1PKL%KZ3MKONP3IJ MVR4TM\$9I72&;81([;&+0.XQ&9TB/# F\ZB#IVE7]6,(=H_[M"!OR8"DC:\3 M\$ML+U?HS6G1E3!C*M(8)*#U@&!88$3+'--1J8C=!C3^I=7Q>Q9W@.&D(&YA M-&E[Z[2Q_<]Y3JX6KBYGCM+<];>WF?2X&-?:$ATC)3F+5 4'$5?K273>,;<# M7#X_?%N(3-K!6F?5NTM_9JLY#+<]<\]<)G&U[;->]<7<]3>[L&]8Q,48SX-( MV\;89G4':$T.YA9V1]BJ>K> 9H[I]N^FONC.L$V2V6Q[V.O4*Y_I"4K7QI'(>^YYYK'5[RZE+] M\:?'V33XKLI%7LS?G\"WX4F@YJ*0^?SF_ AKVZ#ZE8%?Q;EM_P["[Y,6945Y0R #_7'SHN[IS*_ MN:V"*(S0>MCZK^6[4$6$"A@"Q)D *$PY("&,08R1(!D4+ K5#S?OJ*2"8"@ M96D$$(TPH(A1$/&(4I0A*1->&YWF\V_OS#^<+52@ZG# MP\/;1UY.WQ;ES6D4AO'I>O3):OCCWOB'N!X-*:6G]5\W0Q=YTT!M%I[^]?OE ME;A5,P;R^:)B]UZ^@=83Y#:R' ?,6@!&(X=O'A3SY M\"8(EN$HBZGZJK+ _/SCZT4K)#TU(T[GZL9\MU]4F1?RJF)E=Y8-5Y2XR5,C9?_; ,['>#^@?RM]GT]@',U MW4^'\K$KII\.YNZUGB'4\1W>@AGL\O*"^CB78UV[&ZC!KA_?XT-=%D7%IB-< M%L\P6RY/S1N7^M4*QACJF$QKG-74O>6J>JS47*KE;+EC.LCE^Q/]:B)5/EGG MO/KLH4]AF9?]=SDE1ZL<2G2D/J>3;_H@*JR5'JQ4(AO MOZL95^5$1 *F490! C$""$8*T)C$0-!4I(Q%C(2)C1*'.'%DL2[="LZ"9\>" M9\^"C6O!QK>@=LY.S(.BWZWWL6+J-B7XAC/X>^G9_T:(JUS)J]XHO'I\=[QY MOFH^1%Q6L[QY98,3'+1YLZ+F;[B MA#*7W;59IY6?,PTQR1*J4L$)( G- !((ZXE?)8"F3#+$PS16PG;AU0YSY E= M P.QA1PLH8,:VWX)UA&F_G788H%F, M=A/F_0+<,'8W.9^RQ>)S5BO]EV+&\OD$B2BB*2% H42+,L1:E"2* 4\RE80R M481(&U&V0QQ9D#5@4&3K1+\$M4ST'8'IEN%AZ+I)T)6IM?CZR30(+V,+7M-9 M?7JI/C6M%NMWGF78 3"*!/L)KN5G,=(])UX5TUSD53Z_^5WOM,J<32:QCE+N(SO/JZ:Q4[+R0:A*G0B6*:]&D@@"$ M. 0DT^O)F,@PC+#$*&2V\MDV?.QE_\[OZXD@%"P43 M", M17HYIR5"62R!S%*I9!@KQJV%T0YS9)DL@8,5\@_!$CO0X(ZZZ0A4OXH.0]]- M4[[,G4363\Q+2*]"@1@TTK*L67\;%5H8#V'HIT)ZH MA_1:R Q0W4N+(PNNA="^UMH&#LR!)J]^+J^+A_F$4\:2Q%058:@W5AE"@!(B M $MAK%)%(D53KP3XC#%R]JO76449&&C/U+<5'\>\Y\=Z6-*S(NR?\?8I#4]W M6S9?)]?MDVI-= U#/4H:2MR7VM#'1W&KOTOUBGS-$USE]:,.+7>355DRA+)(9Q @23!"#%,2",42"RA'$N M)SWY4'33DBL[+S&]I#%(2!MC MHXOH)8TF >V-<1?/G]I.I>;F]MG]/%\V:R\F.!20Z*T6B#*M&X01!ESI?U1( M=8)*<8J)]:*P$>'(,EIA!KN@]BIJCDJ_E 9S==.3(TTG.752\=)4L\71A-5) M:%M=W0/=);9N'[R8FQ,CM;G+?*XN*C5;3!B&2@IB[B1G$B >24!X'((4JT3+ M#&-$K.L<74!'%MRF]70+._C;H W"YR@UIQ M&PV/WI';1:^I,;=SO+M@S:&EZ9?;8JX^W2\[%#D-(50Z"1*5 )3@$%"89#J$ ME&.59CQ#UB)]:?S(PJSA@AHO6 +:*W$O#OWJ&\+.37$.Q)PDUL; 2U9[QD:3 M4AN-;?FTCG&7S'7)S&G*JZ<9+Z83&B?TTQF.(T 1]"T982FCY"82D6F&%4P M(ERY%=\[\<8IQ.^X\$-0.V'*TRM'O&Y)=X?1MD9_L.!XU>L'Q<6C?&_%=D I MO]O^R&5]*[+[)7Z[CPV\VU;;_5Q^*8OON:8S26-*8*HX4+&,M.II!D@<*Q"K M5(0BQ@QSJV-VGX M=>[*M=!KO377-M[W3.;/[J?7XCCB88H5D$AB@$A* $\I UK5*"0XQ FS:DP> MXL31[_/5A]M^/O:93(_H=\\-8\74;=[P#:?WF4R/N+J>R3QN? >=R3S<9>MQ M)M,_+KUG,CU,CWPFTY_\_IG, ;8&G\F\6"SN5;E]Y#".DA3IF1U0JC(SZ5- M.4R @BC*PHA3%L:>)S/WP(X\N>^=4UPZ<)ACFON1ZU_,'3(>;A/SH% ,.;G9 MRO$0YS?WC;_6*.!;I&G'%VZFOH8(D=K,!=M^G-D;+= MI0_F[[5)=Z7NL4/O)#9@@]YL=^3]>2>Y_>UY]W#_%HIK_=$)P9SQ# F0)B0& M"(L,$(0XD)*04"6)%-SZL1C;AL=JD3!8[NT0-?5^D?D2OUH9MQP>U M,M2&1F]=V':_J55AY^_N0CC3-J2Q\^N4W4Q@!B/,J 0IBJ1Y%H4"+$L02#!' MD'&<$6CU+(H]RT>6P@8K,&#V6MAEWR\&;TYN:K"DXR2'1M>]]+!K:31!-!+8 M5D3S +_GM-1U8&-K^S$49X_Y8B)0+$(9:HFD1B(HS@"C% *<"!(R@2B-K!Y> MV8MT9,F\?):)@71\9DM[D+J5=%#JCELC)];.SV_I972@Q[BTXXSZ-)=>NB\? MZM+_@8-TPUZ;6MXD4CR!4"0 $I::)CL,&(F9Z;1+4BE#&"/K9-8&,M82;Z<+ MM$8>U@"[C)#]ZF\(;\^5H OEH3VO.YP.U>^Z-/J:O:X[M'KZ7'?'^A8]?LVG MZ]Y.O5K,<,8A$&E" >)Z5\42$H%889Q@D<@TM>[9>VE\G/*&P7/N<=V+@VT= MPX^=5_'"AIA'P6*?P8 JQ9:QD4L3^S3VZQ$-8WPE<\T>+Z368IZMCH:LKAM* M4A1'*@&1)/4#*_1>+,4)H-B4"4.D6$3<]-."-(Z8-'BPB^XIK;9XV>KL %'P M$IU[ #PDV$-N@![;+(\LSAZ"^TKM^\# 5KS5C\M\KN!$$AJG'"M HA0!)&() M&$8QR$(A(IQR+K!U(;$591RY;IK05B\"@QU\GOOVX.W$R5:J ]E[R=2=N'_S M71.QX9UW.U9?I^VNB5AKSUWC8%]9?E4WN;F!-Z_JAS]D"F(ITDQO^F "$$TX M((37#]=-((V5C#+'SMA=@''$^(SI^$",QIC8JL^?J9?P;$EZR*V9R0"EO3 X MLLB:Z>SKJV5)W]4]:?\LYV<%K9-5;U MZ%7_L>-J>5WGLWD[H9CR5;/5N_5S'*DVGF#$G?6(8^F0QH0AIKC7B7A+> C"]33!O MV^7SZ?3R\O+PRM7%857/IA1C-EVU/KAM?G6O_27K6Q-CS+1_]TO3)G^H(=R6 M3/]\_^[,S^/"HKQL6EOZSD"3/V_ZB^\J;]M>]9_V:_)HB^X_M&J&NDN(4,3( MX543#EX]FTQNY*BK(GZ,:=+]_OWCR1V3,';S:(MV[FT=ZYBW]-!7BVG7='I< M 1JG=M9UO+]1>[V,+P^:?+$LOER;US'!'7V+N@'&C*K.^K^_?G;ZM2/+.C9 M3^_X.[AP>XO.V-A.Q:LVEB'>N+VR5U3^3J.B$[VJ5Y\LK(M%?S4+,<_Z.Q^Y MIJVM;[.DI(O&6R#. )U<$F0%2TG51UB#=%F9=K6_AX!=SF_;3%= @YEB_P\ M+\+JTZFN%IL8P[;:L*(W0P==/YB BG6=0SO;D;N44=[+UN(Q[%ON2X5%PV: M6;O,SD#TV#ER7-BF^9#.VLI_.KK*FPQ[K;U3 G'AX84KB*?)>"2$X20%"E*% M'Z"1;./Z7M]:NN$C%FVSNO(5E)]V9GNT;&::J-:;Y$66/FSLUCGL3DZ MOEA<0/J7?X9L(T1(#3;#),A3V MJH0ZY#CN-J'1JT25I-)N.I_^8GT[&&T\2]JHR#L"RSFTS806)$KGD-7:($XA MG&II-)+,QV ,#23)C<#16=NIE'G-L7L B"<+N2, 0/C+J_"F#*\A-X1W$F5, M,I@'!*:%X#!!5(1-J&_TQSO*N M&%&VO]E%S P325"K4"26@1H0,2TLQRAI0KE6UFI'1Z'QD-5!9+"](6.TL#L! MQDGIJWI9U;TH_9[RN+HHV_KZN HQ4\F(E&1 1FN%N('PIYW6"!OF*+5)4CHN MA SHQ"!L^)YALSG9=X*BMWD1?[OHDVSEE30L2,0,A23;2]C)I6!0@N2;6A$X MPWP#R'RU.(@/L6=\K"GH3L!P;J]. LB2I_SFV=*M(XP+:PC3B% &^SU-@6\L M#6+10WA,U@F[B6#RB/E!F,@]PV034N\$,T4@FE%#<$-&MI0*V MZU$A1R'GTI@I3C1E#G]?E%N'EP=,#V)%[1DK8R7>)4Z.X<\/]7EUV5616+ X M8)22P[!6:HLL31Q1A9TE0F/)?_0HX(F4?#4\B!&]GXRL*>\N$=+G5!_JT[KZ MG)<^9CPIV+W#*DJ-Z!-S@HS!&C&>A/1&):)^]*#QB9A\9WT0*V8_61DC]"X! M,BM=2#RJH^W[3;4(@H2$G' :<1Z[4V#$HB A'F+)1&0CS^1\8VT8#_M3 M9%U;R2T3T)V4*T[G5;G:F&$.FS%))'*A2[(39%#&$=P]4Y+&?^=[B M,!+VI[8Z2M$MT_!'G;=M+(^KQ>*BO-U\-5D,AE':\2M,1-P:C:Q,O3\1>L^T M"^-.NCUH=A@7^U-9':_MEN$XJXKSMY#9*.(.0IY- M42(M9* &P\^]A_]/(^.^S6%8[$_E=*2J6V;BM(X=T!%RY/X18W=*N/Z04E?A MDRDJPB#.*=<=?F&P"&(.6R[.L(,=.DW,CV+C<=O#&-F?ZNF&5-XM5DZ:YB+6 MW_IBA- 25DK$M8>%,BH/W#N!:""$JZ2#Q^.BR<]Z,(R;_2FG;E3Q;:\^T5_ M"GH-SI_G;1$S(A).@4?H;("^DT"0Y@K(%R+!@AHU_(Q;>[ZS.(R._2F@CE)T MRS28P5JX[ST*X9\"RMDBGA)$B"8O@8N))C4+ACKEA'.Q/ MD71]+7XI,RR-%MP@A*K QM6X'K(Z M#(G]J86.5G8G:J!O%K&> =G_K:O+=@XKX=*6U_"^HT;Y!.ET4)!==XEUPD"Y M881ZAJ52X\Z9_L#XL&-D^U8%':_SEG$Y F%")\[;PLXR%ADX'&!+CB5$P"@5 MLBPJA#&Q3#/OB!RWFMPQ-PR)_2F$KJ_E3L2,8^AY;8L3R)&O_A>O,T^YL) 6 MP7(H7/?=(XNO9_4$L! A0#% @ 3SE]6+(!JWS'/@ U3$" ! M ( ! &AC="TR,#(T,#,R-RYH=&U02P$"% ,4 " !/.7U8]R@8 MG%0# E# $ @ 'U/@ :&-T+3(P,C0P,S(W+GAS9%!+ M 0(4 Q0 ( $\Y?5C]!@EY=0@ !H] 4 " 7=" !H M8W0M,C R-# S,C=?9&5F+GAM;%!+ 0(4 Q0 ( $\Y?5@3$6G6L0P /EN M 4 " 1Y+ !H8W0M,C R-# S,C=?;&%B+GAM;%!+ 0(4 M Q0 ( $\Y?5AM8E90*@@ , _ 4 " 0%8 !H8W0M F,C R-# S,C=?<')E+GAM;%!+!08 !0 % $(! !=8 ! end XML 17 hct-20240327_htm.xml IDEA: XBRL DOCUMENT 0001561032 2024-03-27 2024-03-27 0001561032 hct:SeriesACumulativeRedeemablePerpetualPreferredStockMember 2024-03-27 2024-03-27 0001561032 hct:SeriesBCumulativeRedeemablePerpetualPreferredStockMember 2024-03-27 2024-03-27 false 0001561032 8-K 2024-03-27 Healthcare Trust, Inc. MD 001-39153 38-3888962 222 Bellevue Ave. Newport RI 02840 212 415-6500 false false false false 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIA NASDAQ 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIBP NASDAQ false 2024-03-27